Reassessing The Changing Outlook For Cardiff Oncology Inc. (NASDAQ: CRDF)

    0
    71

    Caxton Corp. recently announced the acquisition of new stake in Cardiff Oncology Inc. (NASDAQ:CRDF). This fresh investment now brings its stake to 9.81% valued currently at $9.81 million. In addition, Northern Trust Investments, Inc.(. raised its holdings by 10087.0 to 10087.0 shares. And UBS Securities LLC has lifted its position by 8,131.68% or 8213.0 shares – to 8314.0 shares.

    With over 0.53 million Cardiff Oncology Inc. (CRDF) shares trading Friday and a closing price of $4.53 on the day, the dollar volume was approximately $2.41 million. The shares have shown a negative weekly performance of -4.03% and its price on 07/17/20 lost nearly -4.83%. Currently, there are 9.91M common shares owned by the public and among those 9.73M shares have been available to trade.

    An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for CRDF have a consensus price objective of $14.50. The analysts have set the share’s price value over the next 12 months at a high of $23.00 and a low of $6.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Cardiff Oncology Inc. stock is 2.00 for the next 12 months. But an upside of 80.3% will see the stock hit the forecast high price target while mean target price for the stock is $14.50.

    Insiders at the company have transacted a total of 14 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 11 of these insider trades were purchases, accounting for 597,376 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 1,134 shares.

    The top 3 mutual fund holders in Cardiff Oncology Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.22 million shares of the company’s stock, all valued at over $1.09 million. Fidelity Extended Market Index Fu bought 23695.0 shares to bring its total holdings to over 39506.0 shares at a value of $0.2 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.20% of the shares outstanding.

    Shares of Cardiff Oncology Inc. (NASDAQ: CRDF) opened at $4.80, up $0.04 from a prior closing price of $4.76. However, the script later closed the day at $4.53, down -4.83%. The company’s stock has a 5-day price change of -4.03% and 386.05% over the past three months. CRDF shares are trading 265.32% year to date (YTD), with the 12-month market performance up to 111.68% higher. It has a 12-month low price of $0.70 and touched a high of $5.75 over the same period. Currently, 0.53 million shares have been traded, compared to an average intraday trading volume of 931.18K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.42%, 44.85%, and 152.50% respectively.

    Institutional ownership of Cardiff Oncology Inc. (NASDAQ: CRDF) shares accounts for 21.60% of the company’s 9.91M shares outstanding. Mutual fund holders own 10.79%, while other institutional holders and individual stakeholders account for 3.12% and 1.75% respectively.

    It has a market capitalization of $94.99M and a beta (3y monthly) value of 1.48. The earnings-per-share (ttm) stands at -$2.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.84% over the week and 12.41% over the month.

    Analysts forecast that Cardiff Oncology Inc. (CRDF) will achieve an EPS of $0 for the current quarter, -$0.24 for the next quarter and -$1.06 for 2021. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$1.02 a year ago. Earnings per share for the fiscal year are expected to increase by 66.20%, and 0.90% over the next financial year.

    If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Cardiff Oncology Inc. (CRDF) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here